Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000698078 | SCV000826720 | uncertain significance | Epileptic encephalopathy | 2024-09-21 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 342 of the FASN protein (p.Ala342Ser). This variant is present in population databases (rs760665615, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with FASN-related conditions. ClinVar contains an entry for this variant (Variation ID: 575765). An algorithm developed to predict the effect of missense changes on protein structure and function outputs the following: PolyPhen-2: "Possibly Damaging". The serine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV000698078 | SCV000895146 | uncertain significance | Epileptic encephalopathy | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004026427 | SCV004869669 | uncertain significance | not specified | 2023-10-05 | criteria provided, single submitter | clinical testing | The c.1024G>T (p.A342S) alteration is located in exon 8 (coding exon 7) of the FASN gene. This alteration results from a G to T substitution at nucleotide position 1024, causing the alanine (A) at amino acid position 342 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003411625 | SCV004114611 | uncertain significance | FASN-related disorder | 2024-06-25 | no assertion criteria provided | clinical testing | The FASN c.1024G>T variant is predicted to result in the amino acid substitution p.Ala342Ser. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.025% of alleles in individuals of Latino descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |